EYSUVIS Drug Patent Profile
✉ Email this page to a colleague
When do Eysuvis patents expire, and what generic alternatives are available?
Eysuvis is a drug marketed by Alcon Labs Inc and is included in one NDA. There are sixteen patents protecting this drug.
This drug has eighty-four patent family members in twelve countries.
The generic ingredient in EYSUVIS is loteprednol etabonate. There are ten drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the loteprednol etabonate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Eysuvis
A generic version of EYSUVIS was approved as loteprednol etabonate by SENTISS on April 17th, 2019.
Summary for EYSUVIS
International Patents: | 84 |
US Patents: | 16 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 65 |
Clinical Trials: | 1 |
Patent Applications: | 4,910 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for EYSUVIS |
What excipients (inactive ingredients) are in EYSUVIS? | EYSUVIS excipients list |
DailyMed Link: | EYSUVIS at DailyMed |
Recent Clinical Trials for EYSUVIS
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Price Vision Group | Phase 4 |
Kala Pharmaceuticals, Inc. | Phase 4 |
Pharmacology for EYSUVIS
Drug Class | Corticosteroid |
Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
Anatomical Therapeutic Chemical (ATC) Classes for EYSUVIS
US Patents and Regulatory Information for EYSUVIS
EYSUVIS is protected by sixteen US patents.
Patents protecting EYSUVIS
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: ADMINISTRATION TO THE EYE OF A PATIENT FOR TREATMENT OF DRY EYE CONDITION
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A COMPOSITION TO A MUCUS MEMBRANE
Nanocrystals, compositions, and methods that aid particle transport in mucus
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR DELIVERING A PHARMACEUTICAL AGENT ACROSS A MUCOSAL BARRIER
Compositions and methods for ophthalmic and/or other applications
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: A METHOD FOR TREATING DRY EYE IN A PATIENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Alcon Labs Inc | EYSUVIS | loteprednol etabonate | SUSPENSION/DROPS;OPHTHALMIC | 210933-001 | Oct 26, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for EYSUVIS
See the table below for patents covering EYSUVIS around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Canada | 2928969 | COMPOSITIONS ET PROCEDES POUR APPLICATIONS OPHTALMIQUES ET/OU AUTRES APPLICATIONS (COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2015066444 | ⤷ Sign Up | |
European Patent Office | 2844227 | NANOPARTICULES PHARMACEUTIQUES PRÉSENTANT UN TRANSPORT MUQUEUX AMÉLIORÉ (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) | ⤷ Sign Up |
World Intellectual Property Organization (WIPO) | 2013166436 | ⤷ Sign Up | |
European Patent Office | 3062796 | COMPOSITIONS ET PROCÉDÉS POUR APPLICATIONS OPHTALMIQUES ET/OU AUTRES APPLICATIONS (COMPOSITIONS AND METHODS FOR OPHTHALMIC AND/OR OTHER APPLICATIONS) | ⤷ Sign Up |
Canada | 2871748 | NANOPARTICULES PHARMACEUTIQUES A TRANSPORT MUCOSAL AMELIORE (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) | ⤷ Sign Up |
China | 111700879 | 显示提高的粘膜转移的药物纳米粒子 (PHARMACEUTICAL NANOPARTICLES SHOWING IMPROVED MUCOSAL TRANSPORT) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |